The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.

Di Giacomo AM, Simonelli M, Losurdo A, Spiliopoulou P, D'Alonzo V, Amato G, Valente M, Barcenilla H, Johnsson A, Gonzalez L, Tan Z, Tadepally L, Brodin P, Lahn M, Di Conza G, Zorrilla R, van der Veen L, Bevilacqua A, Kaur P, Hammett T, Durini M, Corsi A, Sindhwani N, Occhipinti M, Snijder R, Abdul-Ahad A, Meijer A, Postiglione U, Price G, Hopton G, Wood E, Vuaroqueaux V, Peille AL, Graham J, Poi M, Spetzler D, Carlo-Stella C, Santoro A, Evans TRJ, Maio M.

Open source

DOI
10.1038/s41467-026-77358-7
Published
2026-10-09
Container
Nat Commun
Publisher
Not recorded
Open access
no

Credibility signals

uncertain Score 51/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41467-026-77358-7,
  title = {The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.},
  author = {Di Giacomo AM and  Simonelli M and  Losurdo A and  Spiliopoulou P and  D'Alonzo V and  Amato G and  Valente M and  Barcenilla H and  Johnsson A and  Gonzalez L and  Tan Z and  Tadepally L and  Brodin P and  Lahn M and  Di Conza G and  Zorrilla R and  van der Veen L and  Bevilacqua A and  Kaur P and  Hammett T and  Durini M and  Corsi A and  Sindhwani N and  Occhipinti M and  Snijder R and  Abdul-Ahad A and  Meijer A and  Postiglione U and  Price G and  Hopton G and  Wood E and  Vuaroqueaux V and  Peille AL and  Graham J and  Poi M and  Spetzler D and  Carlo-Stella C and  Santoro A and  Evans TRJ and  Maio M.},
  year = {2026},
  journal = {Nat Commun},
  doi = {10.1038/s41467-026-77358-7},
  url = {https://doi.org/10.1038/s41467-026-77358-7}
}

RIS

TY  - JOUR
TI  - The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.
AU  - Di Giacomo AM
AU  -  Simonelli M
AU  -  Losurdo A
AU  -  Spiliopoulou P
AU  -  D'Alonzo V
AU  -  Amato G
AU  -  Valente M
AU  -  Barcenilla H
AU  -  Johnsson A
AU  -  Gonzalez L
AU  -  Tan Z
AU  -  Tadepally L
AU  -  Brodin P
AU  -  Lahn M
AU  -  Di Conza G
AU  -  Zorrilla R
AU  -  van der Veen L
AU  -  Bevilacqua A
AU  -  Kaur P
AU  -  Hammett T
AU  -  Durini M
AU  -  Corsi A
AU  -  Sindhwani N
AU  -  Occhipinti M
AU  -  Snijder R
AU  -  Abdul-Ahad A
AU  -  Meijer A
AU  -  Postiglione U
AU  -  Price G
AU  -  Hopton G
AU  -  Wood E
AU  -  Vuaroqueaux V
AU  -  Peille AL
AU  -  Graham J
AU  -  Poi M
AU  -  Spetzler D
AU  -  Carlo-Stella C
AU  -  Santoro A
AU  -  Evans TRJ
AU  -  Maio M.
PY  - 2026
JO  - Nat Commun
DO  - 10.1038/s41467-026-77358-7
UR  - https://doi.org/10.1038/s41467-026-77358-7
ER  -

APA

AM, D. G., M, S., A, L., P, S., V, D., G, A., M, V., H, B., A, J., L, G., Z, T., L, T., P, B., M, L., G, D. C., R, Z., L, V. D. V., A, B., P, K., T, H., M, D., A, C., N, S., M, O., R, S., A, A., A, M., U, P., G, P., G, H., E, W., V, V., AL, P., J, G., M, P., D, S., C, C., A, S., TRJ, E., & M., M. (2026). The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial.. Nat Commun. https://doi.org/10.1038/s41467-026-77358-7

Source records